A Phase-2 NIH-sponsored Randomized Clinical Trial of Rituximab in Scleroderma-associated Pulmonary Arterial Hypertension Did Not Reach Significance for Its Endpoints: End of Story? Not So Fast!
Yongneng Zhang, Evangelos D. Michelakis
Topics & Concepts
MedicineRituximabScleroderma (fungus)Clinical endpointRandomized controlled trialPulmonary hypertensionSurrogate endpointClinical trialEnd pointInternal medicineCardiologyPhysical therapyImmunologyLymphomaInoculationMathematicsGeometryPulmonary Hypertension Research and TreatmentsSystemic Sclerosis and Related DiseasesInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis